Calcification markers and long-term outcomes of coronary artery bypass grafting

Aim. To assess the long-term outcomes of coronary artery bypass grafting (CABG) and their association with calcification biomarkers.

Material and methods. The study included 129 men (mean age, 61,5±7,5 years) with coronary atherosclerosis who were admitted for CABG surgery. Patients were divided into 2 groups: with favorable and unfavorable (death, myocardial infarction, stroke, surgery) 5-year prognosis after surgery. Before the surgery, the blood concentrations of calcification biomarkers (osteoprotegerin, osteopontin, osteonectin and osteocalcin) were determined in all patients.

Results. Long-term outcomes of myocardial revascularization were studied in 92 patients (71%). An unfavorable long-term 5-year period was identified in 28 men (30,4%). In men with an unfavorable 5-year prognosis, the blood osteocalcin level before CABG was 1,2 times higher than in men with a favorable one. Multivariate linear regression showed that the risk of a 5-year unfavorable prognosis for coronary atherosclerosis after myocardial revascularization was associated with the blood osteocalcin concentration, determined before CABG (B=0,018, R²=0,285, p=0,008).

Conclusion. The data obtained indicate the relevance of continuing studies on osteocalcin, including with respect to its contribution to coronary atherosclerosis and calcification.

1. Ndrepepa G, Iijima R, Kufner S, et al. Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. Am Heart J. 2016;177:9-16. doi:10.1016/j.ahj.2016.03.016.

2. Zeitouni M, Clare RM, Chiswell K, et al. Risk factor burden and long-term prognosis of patients with premature coronary artery disease. J Am Heart Assoc. 2020;9(24):e017712. doi:10.1161/JAHA.120.017712.

3. Collet JP, Zeitouni M, Procopi N, et al. Long-Term Evolution of Premature Coronary Artery Disease. J Am CollCardiol. 2019;74(15):1868-78. doi:10.1016/j.jacc.2019.08.1002.

4. Wang X, Cai G, Wang Y, et al. Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia. Lipids Health Dis. 2019;18(1):131. doi:10.1186/s12944-019-1074-8.

5. Nuru A, Weltzien JAH, Sandvik L, et al. Short- and long-term survival after isolated coronary artery bypass grafting, the impact of gender and age. Scand Cardiovasc J. 2019;53(6):342-7. doi:10.1080/14017431.2019.1646430.

6. Gassett AJ, Sheppard L, McClelland RL, et al. Risk factors for long-term coronary artery calcium progression in the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2015;4(8):e001726. doi:10.1161/JAHA.114.001726.

7. Barbarash OL, Kashtalap VV, Shibanova IA, Kokov AN. Fundamental and practical aspects of coronary artery calcification. Russian Journal of Cardiology. 2020;25(3S):4005. (In Russ.) doi:10.15829/1560-4071-2020-4005.

8. Rifai MA, Blaha MJ, Patel J, et al. Coronary artery calcification, statin use and long-term risk of atherosclerotic cardiovascular disease events (from the MultiEthnic Study of Atherosclerosis). Am J Cardiol. 2020;125(6):835-9. doi:10.1016/j.amjcard.2019.12.031.

9. Barbarash OL, Kashtalap VV, Zykov MV, et al. The relationship of the concentration of osteopontin with the severity of coronary atherosclerosis and osteopenic syndrome in men with stable coronary heart disease. Atherosclerosis and dyslipidemia. 2016;4(25):40-8. (In Russ.)

10. Mohamadpour AH, Abdolrahmani L, Mirzaei H, et al. Serum osteopontin concentrations in relation to coronary artery disease. Arch Med Res. 2015;46(2):112-7. doi:10.1016/j.arcmed.2015.02.005.

11. Salari P, Keshtkar A, Shirani S, et al. Coronary artery calcium score and bone metabolism: a pilot study in postmenopausal women. J Bone Metab. 2017;24:15-21. doi:10.11005/jbm.2017.24.1.15.

12. Bao Y, Zhou M, Lu Z, et al. Serum levels of osteocalcinare inversely associated with the metabolic syndrome and the severity of coronary artery disease in Chinese men. ClinEndocrinol (Oxf). 2011;75(2):196-201. doi:10.1111/j.1365-2265.2011.04065.x.

13. Sheng L, Cao W, Cha B, et al. Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes. CardiovascDiabetol. 2013;12:22. doi:10.1186/1475-2840-12-22.

14. Maniatis K, Siasos G, Oikonomou E, et al. Osteoprotegerin and osteopontin serum levels are associated with vascular function and inflammation in coronary artery disease patients. Curr Vasc Pharmacol. 2020;18(5):523-30. doi:10.2174/1570161117666191022095246.

15. Maser RE, Lenhard MJ, Sneider MB, et al. Osteoprotegerin is a better serum biomarker of coronary artery calcification than osteocalcin in type 2 diabetes. EndocrPract. 2015;21(1):14-22. doi:10.4158/EP14229.OR.

16. Kang J-H. Association of serum osteocalcin with insulin resistance and coronary atherosclerosis. J Bone Metab. 2016;23:183-90. doi:10.11005/jbm.2016.23.4.183.

17. Kanazawa I. Osteocalcin as a hormone regulating glucose metabolism. World J Diabetes. 2015;6(18):1345-54. doi:10.4239/wjd.v6.i18.1345.

18. Zhang X, Shen Y, Ma X, et al. Low serum osteocalcin levels are correlated with left ventricular systolic dysfunction and cardiac death in Chinese men. Acta Pharmacologica Sinica. 2019;40:486-91. doi:10.1038/s41401-018-0080-0.